Free Trial

Carmell (CTCX) Competitors

Carmell logo
$0.44 -0.02 (-3.30%)
Closing price 01/23/2025 04:00 PM Eastern
Extended Trading
$0.44 0.00 (-0.68%)
As of 08:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CTCX vs. NXL, MODD, OM, DXR, MDAI, MBOT, NMTC, SURG, POCI, and XAIR

Should you be buying Carmell stock or one of its competitors? The main competitors of Carmell include Nexalin Technology (NXL), Modular Medical (MODD), Outset Medical (OM), Daxor (DXR), Spectral AI (MDAI), Microbot Medical (MBOT), NeuroOne Medical Technologies (NMTC), SurgePays (SURG), Precision Optics (POCI), and Beyond Air (XAIR). These companies are all part of the "medical equipment" industry.

Carmell vs.

Carmell (NASDAQ:CTCX) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

24.2% of Carmell shares are held by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are held by institutional investors. 29.0% of Carmell shares are held by insiders. Comparatively, 24.0% of Nexalin Technology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Carmell has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Nexalin Technology has a beta of 4.24, suggesting that its share price is 324% more volatile than the S&P 500.

In the previous week, Nexalin Technology had 2 more articles in the media than Carmell. MarketBeat recorded 2 mentions for Nexalin Technology and 0 mentions for Carmell. Nexalin Technology's average media sentiment score of 0.75 beat Carmell's score of 0.00 indicating that Nexalin Technology is being referred to more favorably in the news media.

Company Overall Sentiment
Carmell Neutral
Nexalin Technology Positive

Nexalin Technology received 1 more outperform votes than Carmell when rated by MarketBeat users.

CompanyUnderperformOutperform
CarmellN/AN/A
Nexalin TechnologyOutperform Votes
1
50.00%
Underperform Votes
1
50.00%

Nexalin Technology has a consensus target price of $3.00, indicating a potential upside of 15.38%. Given Nexalin Technology's stronger consensus rating and higher possible upside, analysts plainly believe Nexalin Technology is more favorable than Carmell.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Carmell
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Nexalin Technology
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Carmell has a net margin of 0.00% compared to Nexalin Technology's net margin of -3,407.98%. Nexalin Technology's return on equity of -187.59% beat Carmell's return on equity.

Company Net Margins Return on Equity Return on Assets
CarmellN/A -217.50% -50.22%
Nexalin Technology -3,407.98%-187.59%-167.21%

Nexalin Technology has higher revenue and earnings than Carmell.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CarmellN/AN/A-$15.44MN/AN/A
Nexalin Technology$110K314.36-$4.65M-$0.64-4.06

Summary

Nexalin Technology beats Carmell on 9 of the 13 factors compared between the two stocks.

Get Carmell News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTCX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CTCX vs. The Competition

MetricCarmellSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$9.20M$4.91B$5.44B$9.26B
Dividend YieldN/A52.56%5.36%3.98%
P/E RatioN/A14.7161.6413.90
Price / SalesN/A56.921,282.3576.67
Price / CashN/A52.1044.4137.65
Price / Book0.418.135.054.74
Net Income-$15.44M$13.87M$117.90M$224.54M
7 Day Performance-16.22%1.72%2.63%1.24%
1 Month Performance54.55%9.72%3.68%3.17%
1 Year Performance-86.34%34.16%27.48%22.74%

Carmell Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTCX
Carmell
0.3866 of 5 stars
$0.44
-3.3%
N/A-85.8%$9.20MN/A0.0014Gap Down
NXL
Nexalin Technology
2.3924 of 5 stars
$3.16
flat
$3.00
-5.1%
+600.8%$42.03M$110,000.00-4.943News Coverage
MODD
Modular Medical
2.3468 of 5 stars
$1.21
-0.8%
$5.00
+313.2%
-33.2%$41.98MN/A-1.9220Gap Up
OM
Outset Medical
2.964 of 5 stars
$0.79
-3.4%
$4.50
+469.6%
-77.1%$41.51M$130.38M-0.29520Gap Down
DXR
Daxor
3.0512 of 5 stars
$8.50
+5.1%
$24.75
+191.2%
-12.1%$41.14MN/A0.0037Negative News
MDAI
Spectral AI
2.1957 of 5 stars
$1.96
-5.8%
$4.50
+129.6%
-16.2%$36.44M$18.06M-3.0283News Coverage
Negative News
MBOT
Microbot Medical
2.4374 of 5 stars
$1.64
-7.9%
$7.00
+326.8%
+48.1%$33.19MN/A-2.0520Gap Up
NMTC
NeuroOne Medical Technologies
N/A$1.05
+1.0%
N/A-17.0%$32.38M$3.45M-2.2820
SURG
SurgePays
3.0823 of 5 stars
$1.55
-1.9%
$8.50
+448.4%
-75.7%$31.25M$137.14M-1.3740
POCI
Precision Optics
0.5034 of 5 stars
$4.89
flat
N/A-15.7%$31.05M$19.10M-7.8980
XAIR
Beyond Air
4.4239 of 5 stars
$0.42
+11.6%
$3.67
+778.2%
-70.8%$30.14M$1.16M-0.3070News Coverage
Gap Up

Related Companies and Tools


This page (NASDAQ:CTCX) was last updated on 1/24/2025 by MarketBeat.com Staff
From Our Partners